From basic medicine to clinical medicine and medical care
Company Profile   |   tel ＋81 44-201-8518   Japanese

NOG-IL2

Home » Products » NOG-IL2

NOG-IL2

Next Generation Severely Immunodeficient NOG-IL2 mouse

Next Generation Severely Immunodeficient NOG-IL2 mouse
Strain Name NOG-hIL2 Tg (NOG-IL2)
  • You will be required to sign a consent form upon purchase.
  • The use of this mouse strain corresponds to the use of Living Modified Organism (Cartagene Protocol, domestic law). We will send you an information provision form in advance, so please check it and use it according to the rules of each institution.
Contact form Seminar＆Technical Information
Development

A vector containing a human IL-2 signal peptide and a human IL-2 gene downstream of the CMV promoter was microinjected into (NOD♀ x NOG♂) F1 pronuclear stage embryos, and the resulting transgenic mouse were backcrossed to NOG mouse and established.

Product features of NOG-IL2 mouse
  • A transgenic NOG mouse that systemically expresses the human IL-2 gene.
  • Engraftment of human hematopoietic stem cells results in marked differentiation of human NK cells.
  • Myeloid lineages and B cells are differentiated to the same extent as in humanized NOG mouse.
Research Applications
  • It is widely used for ADCC (antibody-dependent cellular-cytotoxicity) activity evaluation system via human NK cells and functional analysis of human NK cells.

Humanized NOG-IL2 mouse

  • We produce humanized NOG-IL2 mouse in Japan and deliver them to customers.
  • Production will be started after receiving your firm order.
  • Unlike conventional humanized NOG mouse, the number of NK cells increases rapidly after HSC transfer, so early shipment is recommended.
  • You will be required to sign a consent form upon purchase.
  • The use of this mouse strain corresponds to the use of Living Modified Organism (Cartagene Protocol, domestic law). We will send you an information provision form in advance, so please check it and use it according to the rules of each institution.
Contact form HSC engraftment Seminar＆Technical Information
Product features of Humanized NOG-IL2 mouse
  • When HSCs are engrafted into NOG-IL2 mouse, HSCs differentiate more efficiently than conventional NOG mouse.
  • Within 4 weeks after HSC engraftment, human CD45 positive cells were reported to be significantly increased in peripheral blood compared to humanized conventional NOG mouse.
  • Flow cytometry analysis showed that NKp46 positive CD56 positive CD3 negative cells were predominantly differentiated, suggesting that they were NK cells.
  • It was reported that the absolute number of CD56 positive human NK cells in NOG-IL2 mouse engrafted with human HSCs was more than 10-fold higher than in conventional NOG mouse engrafted with human HSCs.
  • NOG-IL2 mouse are expected to facilitate in vivo analysis of human NK cells and can be used to evaluate various therapeutics.（Katano et al. J Immunol 2015）
  • We provide detailed briefings by online regarding the characteristics of humanized mouse, the production of humanized mouse, and experimental protocols for use. Please feel free to contact us at sales@invivoscience.com.
Background data

References

Sustaining the T-cell activity in xenografted psoriasis skin.(Xenograft; psoriasis skin; human T-cell activity; IL 2 NOG mice)
PLoS One. 2023 Jan 17;18(1):e0278390. doi: 10.1371/journal.pone.0278390. eCollection 2023.
Christensen PKF, Hansen AK,Skov S, Engkilde K, Larsen J, Høyer-Hansen MH, Koch J.

Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse. (Original, humanized mice, NOG-IL2, NK Cells)
J Immunol. 2015 Apr 1;194(7):3513-25. doi: 10.4049/jimmunol.1401323. Epub 2015 Feb 23.
Katano I, Takahashi T, Ito R, Kamisako T, Mizusawa T, Ka Y, Ogura T, Suemizu H, Kawakami Y, Ito M.

Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. (humanized mice, NOG-IL2, melanoma PDX)
Ann Oncol. 2020 Feb;31(2):266-273. doi: 10.1016/j.annonc.2019.11.002. Epub 2020 Jan 3.
Ny L, Rizzo LY, Belgrano V, Karlsson J, Jespersen H, Carstam L, Bagge RO, Nilsson LM, Nilsson JA.

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. (Uveal melanoma, T cell therapy-resistabt melanoma, CAR-T,NOG-IL2)
Cancer Res. 2019 Mar 1;79(5):899-904. doi: 10.1158/0008-5472.CAN-18-3158. Epub 2019 Jan 8.
Elin M V Forsberg, Mattias F Lindberg, Henrik Jespersen, Samuel Alsén, Roger Olofsson Bagge, Marco Donia, Inge Marie Svane, Ola Nilsson, Lars Ny, Lisa M Nilsson, Jonas A Nilsson

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. (humanized mice, NOG-IL2, adoptive T-cell transfer)
Nat Commun. 2017 Sep 27;8(1):707. doi: 10.1038/s41467-017-00786-z.
Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA.